BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-923@pharmaconomics
DTSTAMP:20260707T042408Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:AVTX Phase 2 — AVTX-009
DESCRIPTION:Phase 2 trial results for AVTX-009 in Hidradenitis Suppurativa (HS) are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000003/ex-991xavalocorporatepre.htm\n\nTrack it: https://pharmaconomics.com/e/923
URL:https://pharmaconomics.com/e/923
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AVTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR